Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

HHS Final Rule Reinstates ACA Nondiscrimination Provisions

  |  

Effective July 5, discrimination based on race, color, national origin, sex, age and disability by healthcare programs receiving federal assistance is once again prohibited. The application of Section 1557 to all HHS health programs and activities and state and federally facilitated exchanges, which had been weakened by the Trump administration, has been reinstated.

What Rheumatologists Need to Know About Antiphospholipid Syndrome

Yu (Ray) Zuo, MD, MS, & Jason S. Knight, MD, PhD  |  

Antiphospholipid syndrome (APS) is an acquired thromboinflammatory disease that can have severe, sometimes catastrophic, effects on patients and their families. Our modern understanding of APS began to emerge in the early 1980s. At that point, it was defined as a condition characterized by thrombotic episodes and/or pregnancy complications in the presence of antiphospholipid antibodies (aPL).1…

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

  |  

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Calprotectin Shows Promise as APS Thrombocytopenia Biomarker

  |  

Hoy et al. sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of patients with primary antiphospholipid syndrome (APS) and those with antiphospholipid antibodies. Calprotectin levels were higher in patients with primary APS and those with antiphospholipid antibodies than in healthy controls. These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS-related thrombocytopenia.

A Fellow’s Experience at Advocacy 101

Audrey Liu, MD  |  

Rheumatology fellow Audrey Liu, MD, describes the excitement and empowerment of seeing first-hand the real-world impact of advocating for policies that support providers and patients.

ACR Hill Day Participants Urge Congress to Reform Medicare Reimbursement

  |  

On May 6–7, nearly 100 rheumatologists and rheumatology professionals converged in Washington, D.C., for the ACR’s annual Advocacy Leadership Conference and 137 meetings on Capitol Hill. You can help extend the efforts of these advocates and amplify their impact by contacting your lawmakers via the Legislative Action Center.